Jake Chabon
About
Detail
Co-founder/CEO
Denver, Colorado, United States
Résumé
Jobs
verified_user
0% verified
Co-founder/CEOForesight Diagnostics a Natera companyOct 2020 - Current (5 years 9 months)Foresight Diagnostics is an early-stage, venture-backed molecular diagnostics company that is developing non-invasive cancer detection technologies to improve the lives of patients worldwide. Our portfolio of cell-free DNA based liquid biopsy tests are rooted in novel and proprietary methods developed at Stanford University. Our approach enables the earlier detection of smaller tumors, leading to more personalized and effective cancer treatment strategies for patients. We have deep expertise in molecular biology, bioinformatics, and Next Generation Sequencing (NGS).- Postdoctoral FellowStanford UniversityJun 2018 - Oct 2020 (2 years 5 months)
- PHD CandidateStanford University School of MedicineSep 2013 - May 2018 (4 years 9 months)PhD program in Stem Cell Biology and Regenerative Medicine
- UProfessional Research AssistantUniversity of Colorado at Denver and Health Sciences CenterOct 2010 - May 2013 (2 years 8 months)
- InternSomaScanJun 2009 - Sep 2009 (4 months)
- Research AssistantUniversity of DenverJan 2008 - Jun 2010 (2 years 6 months)
Education
verified_user
0% verified
- Doctor of Philosophy - PhD, Stem Cell Biology and Regenerative MedicineStanford UniversityJan 2013 - Dec 2018 (6 years)
- Griffith UniversityGriffith UniversityJan 2008 - Dec 2009 (2 years)Cherrington Global Scholar- Member of Cherrington study abroad program in Australia
- BS, Molecular Biology, Pre-med. Triple Minor in Business Administration, Chemistry, & Psychology.University of DenverJan 2006 - Dec 2010 (5 years)Graduated Magna Cum Laude with University Honors and departmental distinction in Biological Sciences with a cumulative GPA of 3.92.
Publications
verified_user
0% verified
- NIntegrating genomic features for non-invasive early lung cancer detectionNatureMar 2020
- CCombination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcomaClinical Cancer ResearchJun 2018
- NEvolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersNature GeneticsNov 2017
- CEarly detection of molecular residual disease in localized lung cancer by circulating tumor DNA profilingCancer DiscoverySep 2017Identifying molecular residual disease (MRD) after treatment of localized lung cancer could facilitate early intervention and personalization of adjuvant therapies. Here we apply Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) circulating tumor DNA (ctDNA) analysis to 255 samples from 40 patients treated with curative intent for stage I-III lung cancer and 54 healthy adults. In 94% of evaluable patients experiencing recurrence, ctDNA was detectable in the first post-treatment blood sample, indicating reliable identification of MRD. Post-treatment ctDNA detection preceded radiographic progression in 72% of patients by a median of 5.2 months and 53% of patients harbored ctDNA mutation profiles associated with favorable responses t
- SDistinct biological subtypes and patterns of genome evolution in lymphoma patients revealed by circulating tumor DNAScience Translational MedicineNov 2016
- NCirculating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsNature Communications
- NIntegrated digital error suppression for improved detection of circulating tumor DNANature Biotechnology
- AInter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinibASCO Annual Meeting